How much do paid clinical trials in Springfield pay?

Compensation varies by study length, procedures and overnight stays. Industry surveys report typical payments from $75 to $4,500 per completed study, with simple observational studies at the low end and multi-week inpatient Phase 1 studies at the high end. Each listing's study team will confirm the exact amount before you enroll.

Do I need to be sick to join a clinical trial in Springfield?

No. Many studies recruit healthy volunteers, especially early-phase studies run at dedicated research centers. Others need participants diagnosed with a specific condition. Every trial lists its eligibility criteria — age range, condition, medications — and the study team screens you before enrollment.

How do I join a study in Springfield, MO?

Pick a study that matches your profile, contact the research site (or apply through the study links on this page), pass a phone pre-screen, then attend an in-person screening visit. If you qualify, you review and sign the informed consent and the study begins. The process typically takes 1-3 weeks.

How often do new paid studies open in Springfield?

Constantly — trials open and close enrollment every week. This page is refreshed weekly from the NIH registry. Join the email alert to be notified when a new study opens within 30 miles of Springfield.

Can I be in more than one clinical trial at a time?

Generally no — most studies exclude participants currently enrolled in another trial, and paid Phase 1 studies enforce a washout period (often 30 days or more) between studies. Frequent healthy volunteers in Springfield typically complete one or two studies per year.

Paid Clinical Trials Springfield, MO — 157 Studies Recruiting (Jul 2026)

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

Fibromyalgia Phase 3 Interventional 620 participants sought

Clinical Research Site — Springfield, Missouri (1.5 mi) · Sponsor: Axsome Therapeutics, Inc.

See eligibility & contact on ClinicalTrials.gov (NCT07398417)

A Study of Dotinurad Versus Allopurinol in Participants With Gout

Gout Phase 3 Interventional 500 participants sought

Delricht Research - Command Family Medicine — Springfield, Missouri (1.5 mi) · Sponsor: Crystalys Therapeutics

See eligibility & contact on ClinicalTrials.gov (NCT07089875)

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma Phase 2 Interventional 188 participants sought

Mercy Hospital Springfield — Springfield, Missouri (1.5 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT04671667)

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Migraine Phase 3 Interventional 200 participants sought

Clinvest Headlands Llc — Springfield, Missouri (1.5 mi) · Sponsor: Pfizer

See eligibility & contact on ClinicalTrials.gov (NCT06616194)

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2 Phase 2 Interventional 270 participants sought

Headlands Research — Springfield, Missouri (1.5 mi) · Sponsor: Novo Nordisk A/S

See eligibility & contact on ClinicalTrials.gov (NCT07415954)

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma Phase 3 Interventional 1,450 participants sought

Mercy Hospital Springfield — Springfield, Missouri (1.5 mi) · Sponsor: ECOG-ACRIN Cancer Research Group

See eligibility & contact on ClinicalTrials.gov (NCT04566328)

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma Phase 3 Interventional 255 participants sought

Mercy Hospital Springfield — Springfield, Missouri (1.5 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT07198074)

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7 Phase 2, Phase 3 Interventional 613 participants sought

Mercy Hospital Springfield — Springfield, Missouri (1.5 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT01810913)

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Ovarian Carcinoma N/A Interventional 1,956 participants sought

Mercy Hospital Springfield — Springfield, Missouri (1.5 mi) · Sponsor: NRG Oncology

See eligibility & contact on ClinicalTrials.gov (NCT04251052)

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Breast Carcinoma, Colorectal Carcinoma N/A Observational 2,000 participants sought

Mercy Hospital Springfield — Springfield, Missouri (1.5 mi) · Sponsor: Wake Forest University Health Sciences

See eligibility & contact on ClinicalTrials.gov (NCT06418204)

A Study of V118E in Healthy Participants (V118E-003)

Healthy Phase 1 Interventional 126 participants sought

Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0004) — Springfield, Missouri (1.5 mi) · Sponsor: Merck Sharp & Dohme LLC

See eligibility & contact on ClinicalTrials.gov (NCT07168915)

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

Cognitive Dysfunction, Lewy Body Disease Phase 2 Interventional 350 participants sought

Citizens Memorial Hospital District — Bolivar, Missouri (29.8 mi) · Sponsor: Eli Lilly and Company

See eligibility & contact on ClinicalTrials.gov (NCT07589595)

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Ovarian Neoplasms, Fallopian Tube Neoplasms Phase 3 Interventional 1,630 participants sought

Cox Medical Center North — Springfield, Missouri (1.5 mi) · Sponsor: Eli Lilly and Company

See eligibility & contact on ClinicalTrials.gov (NCT07213804)

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Stage I Breast Cancer Phase 3 Interventional 1,670 participants sought

Mercy Hospital Springfield — Springfield, Missouri (1.5 mi) · Sponsor: NRG Oncology

See eligibility & contact on ClinicalTrials.gov (NCT04852887)

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Breast Cancer, Cognitive Impairments N/A Interventional 386 participants sought

Mercy Hospital Springfield — Springfield, Missouri (1.5 mi) · Sponsor: NRG Oncology

See eligibility & contact on ClinicalTrials.gov (NCT05896189)

Accelerated ART Initiation for PWHIV Who Are Out of Care

HIV Infections, ART Phase 4 Interventional 120 participants sought

AIDS Project of the Ozarks — Springfield, Missouri (1.5 mi) · Sponsor: University of Missouri-Columbia

See eligibility & contact on ClinicalTrials.gov (NCT06374758)

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Non-alcoholic Fatty Liver Disease Phase 3 Interventional 1,200 participants sought

GSK Investigational Site — Springfield, Missouri (1.5 mi) · Sponsor: GlaxoSmithKline

See eligibility & contact on ClinicalTrials.gov (NCT07221227)

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Intracranial Meningioma, Recurrent Meningioma Phase 2 Interventional 124 participants sought

Mercy Hospital Springfield — Springfield, Missouri (1.5 mi) · Sponsor: Alliance for Clinical Trials in Oncology

See eligibility & contact on ClinicalTrials.gov (NCT02523014)

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Acute Coronary Syndrome Phase 3 Interventional 2,000 participants sought

Research Site — Springfield, Missouri (1.5 mi) · Sponsor: DalCor Pharmaceuticals

See eligibility & contact on ClinicalTrials.gov (NCT05918861)

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain Phase 3 Interventional 200 participants sought

Mercy Hospital Springfield — Springfield, Missouri (1.5 mi) · Sponsor: NRG Oncology

See eligibility & contact on ClinicalTrials.gov (NCT04804644)

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Phase 3 Interventional 3,680 participants sought

CoxHealth South Hospital — Springfield, Missouri (1.5 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT06058377)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma Phase 3 Interventional 1,210 participants sought

Mercy Hospital Springfield — Springfield, Missouri (1.5 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT04267848)

I-DECIDE After Bronchiolitis Hospitalization

Bronchiolitis Acute N/A Interventional 2,700 participants sought

Cox Medical Center South — Springfield, Missouri (1.5 mi) · Sponsor: Seattle Children's Hospital

See eligibility & contact on ClinicalTrials.gov (NCT07243652)

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 Phase 3 Interventional 1,524 participants sought

Mercy Hospital Springfield — Springfield, Missouri (1.5 mi) · Sponsor: Alliance for Clinical Trials in Oncology

See eligibility & contact on ClinicalTrials.gov (NCT06876714)

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Previously Treated Non-Small Cell Lung Cancer Phase 2, Phase 3 Interventional 10,000 participants sought

Mercy Hospital Springfield — Springfield, Missouri (1.5 mi) · Sponsor: SWOG Cancer Research Network

See eligibility & contact on ClinicalTrials.gov (NCT03851445)

Paid Clinical Trials in Springfield, MO

Studies recruiting near Springfield right now

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

A Study of Dotinurad Versus Allopurinol in Participants With Gout

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

A Study of V118E in Healthy Participants (V118E-003)

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Accelerated ART Initiation for PWHIV Who Are Out of Care

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

I-DECIDE After Bronchiolitis Hospitalization

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Top-rated research centers in Springfield

QPS Study Campus

Cancer Research for the Ozarks

DelRicht Research of Springfield Clinical Trials

QPS Screening and Recruitment Center

Clinvest Research

BPVH Clinical Trials

Lakeland Behavioral Health System - Residential

Sharlin Health Neuroscience Research Center

Select Specialty Hospital - Springfield

Clinical trials in Springfield: what's recruiting

How to enroll in a paid study in Springfield

Frequently asked questions

Paid clinical trials near Springfield

More of MO

New paid studies open every week